Related Experiment Videos

Physostigmine and anaesthesia emergence delirium in preschool children: a randomized blinded trial

W Funk1, H Hollnberger, J Geroldinger

  • 1Department of Anaesthesia and Intensive Care Medicine, Klinikum St Marien, Amberg, Germany. funk.wolfgang@klinikum-amberg.de

Insights

Physostigmine did not significantly reduce emergence agitation in preschool children. While not a routine treatment, it may offer therapeutic options when administered carefully to avoid side effects like nausea and vomiting.

Area of Science:

  • Anesthesiology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Severe emergence agitation is common in preschool children post-anesthesia.
  • Symptoms resemble central anticholinergic syndrome.
  • Physostigmine, a cholinesterase-inhibitor, was investigated for efficacy.

Purpose of the Study:

  • To assess physostigmine's effectiveness in treating emergence agitation in children.
  • To identify adverse effects associated with physostigmine use.
  • To evaluate physostigmine as a treatment for post-anesthetic delirium.

Main Methods:

  • 211 children (1-5 years) were anesthetized with sevoflurane.
  • Multimodal pain therapy was administered.
  • Severely agitated children received physostigmine (30 mcg/kg) or placebo in a double-blind, randomized trial.
  • Agitation was assessed using a 5-step score.

Main Results:

  • 19% of children experienced severe delirium.
  • Physostigmine showed no statistically significant reduction in severe agitation at 5 minutes compared to placebo.
  • Postoperative nausea and vomiting increased significantly in the physostigmine group (45% vs. 15%).

Conclusions:

  • The study does not support the routine use of physostigmine for emergence agitation.
  • Physostigmine may be a therapeutic option if administered slowly with prophylaxis for nausea and vomiting.
  • Emergence agitation may be linked to anticholinergic effects.
Abstract

Related Concept Videos

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...